Literature DB >> 21365124

Congenital erythropoietic porphyria: characterization of murine models of the severe common (C73R/C73R) and later-onset genotypes.

David F Bishop1, Sonia Clavero, Narla Mohandas, Robert J Desnick.   

Abstract

Congenital erythropoietic porphyria (CEP) is an autosomal recessive disorder due to the deficient activity of uroporphyrinogen III synthase (UROS). Knock-in mouse models were generated for the common, hematologically severe human genotype, C73R/C73R, and milder genotypes (C73R/V99L and V99L/V99L). The specific activities of the UROS enzyme in the livers and erythrocytes of these mice averaged approximately 1.2%, 11% and 19% of normal, respectively. C73R/C73R mice that survived fetal life to weaning age (~12%) had a severe microcytic hypochromic anemia (hemoglobin 7.9 g/dL, mean cellular volume 26.6 fL, mean cellular hemoglobin content 27.4 g/dL, red cell distribution width 37.7%, reticulocytes 19%) and massively accumulated isomer I porphyrins (95, 183 and 44 μmol/L in erythrocytes, spleen and liver, respectively), but a nearly normal lifespan. In adult C73R/C73R mice, spleen and liver weights were 8.2- and 1.5-fold increased, respectively. C73R/V99L mice were mildly anemic (hemoglobin was 14.0 g/dL and mean cellular hemoglobin was 13.3), with minimally accumulated porphyrins (0.10, 5.54 and 0.58 μmol/L in erythrocytes, spleen and liver, respectively), whereas adult V99L/V99L mice were normal. Of note, even the mildest genotype, V99L/V99L, exhibited porphyria in utero, which disappeared by 2 months of age. These severe and mild mouse models inform therapeutic interventions and permit further investigation of the porphyrin-induced hematopathology, which leads to photo-induced cutaneous lesions. Of significance for therapeutic intervention, these mouse models suggest that only 11% of wild-type activity might be needed to reverse the pathology in CEP patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21365124      PMCID: PMC3146604          DOI: 10.2119/molmed.2010.00258

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  31 in total

1.  Pyridoxal 5-phosphate therapy in a patient with myelodysplastic syndrome and adult onset congenital erythropoietic porphyria.

Authors:  K Yamauchi; Y Kushibiki
Journal:  Br J Haematol       Date:  1992-08       Impact factor: 6.998

2.  Efficient in vivo manipulation of mouse genomic sequences at the zygote stage.

Authors:  M Lakso; J G Pichel; J R Gorman; B Sauer; Y Okamoto; E Lee; F W Alt; H Westphal
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

3.  Congenital erythropoietic porphyria. I. Case report, special studies and therapy.

Authors:  R G Haining; M L Cowger; D B Shurtleff; R F Labbe
Journal:  Am J Med       Date:  1968-10       Impact factor: 4.965

4.  Brown amiotic fluid in congenital erythropoietic porphyria.

Authors:  I H Kaiser
Journal:  Obstet Gynecol       Date:  1980-09       Impact factor: 7.661

5.  Correction of congenital erythropoietic porphyria by bone marrow transplantation.

Authors:  C Thomas; C Ged; Y Nordmann; H de Verneuil; I Pellier; A Fischer; S Blanche
Journal:  J Pediatr       Date:  1996-09       Impact factor: 4.406

6.  Prenatal diagnosis in congenital erythropoietic porphyria by metabolic measurement and DNA mutation analysis.

Authors:  C Ged; F Moreau-Gaudry; L Taine; I Hombrados; P Calvas; P Colombies; H De Verneuil
Journal:  Prenat Diagn       Date:  1996-01       Impact factor: 3.050

7.  Molecular basis of congenital erythropoietic porphyria: mutations in the human uroporphyrinogen III synthase gene.

Authors:  W Xu; K H Astrin; R J Desnick
Journal:  Hum Mutat       Date:  1996       Impact factor: 4.878

8.  [Congenital erythropoietic porphyria. Apropos of a fatal case in the neonatal period due to acute hemolysis with hepatic failure].

Authors:  H de Verneuil; F Moreau-Gaudry; C Ged; M Bensidhoum; I Hombrados; J Tricoire; M Rolland
Journal:  Arch Pediatr       Date:  1995-08       Impact factor: 1.180

9.  Coupled-enzyme and direct assays for uroporphyrinogen III synthase activity in human erythrocytes and cultured lymphoblasts. Enzymatic diagnosis of heterozygotes and homozygotes with congenital erythropoietic porphyria.

Authors:  S F Tsai; D F Bishop; R J Desnick
Journal:  Anal Biochem       Date:  1987-10       Impact factor: 3.365

10.  Successful cord blood stem cell transplantation for congenital erythropoietic porphyria (Gunther's disease).

Authors:  I Zix-Kieffer; B Langer; D Eyer; G Acar; E Racadot; G Schlaeder; F Oberlin; P Lutz
Journal:  Bone Marrow Transplant       Date:  1996-07       Impact factor: 5.483

View more
  6 in total

Review 1.  [Congenital erythropoietic porphyria : An update].

Authors:  C Wenner; N J Neumann; J Frank
Journal:  Hautarzt       Date:  2016-03       Impact factor: 0.751

2.  TMEM14C is required for erythroid mitochondrial heme metabolism.

Authors:  Yvette Y Yien; Raymond F Robledo; Iman J Schultz; Naoko Takahashi-Makise; Babette Gwynn; Daniel E Bauer; Abhishek Dass; Gloria Yi; Liangtao Li; Gordon J Hildick-Smith; Jeffrey D Cooney; Eric L Pierce; Kyla Mohler; Tamara A Dailey; Non Miyata; Paul D Kingsley; Caterina Garone; Shilpa M Hattangadi; Hui Huang; Wen Chen; Ellen M Keenan; Dhvanit I Shah; Thorsten M Schlaeger; Salvatore DiMauro; Stuart H Orkin; Alan B Cantor; James Palis; Carla M Koehler; Harvey F Lodish; Jerry Kaplan; Diane M Ward; Harry A Dailey; John D Phillips; Luanne L Peters; Barry H Paw
Journal:  J Clin Invest       Date:  2014-08-26       Impact factor: 14.808

Review 3.  Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies.

Authors:  Makiko Yasuda; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2019-01-18       Impact factor: 4.797

4.  Abnormal erythroid maturation leads to microcytic anemia in the TSAP6/Steap3 null mouse model.

Authors:  Lionel Blanc; Julien Papoin; Gargi Debnath; Michel Vidal; Robert Amson; Adam Telerman; Xiuli An; Narla Mohandas
Journal:  Am J Hematol       Date:  2015-03       Impact factor: 10.047

5.  Metabolic correction of congenital erythropoietic porphyria with iPSCs free of reprogramming factors.

Authors:  Aurélie Bedel; Miguel Taillepierre; Véronique Guyonnet-Duperat; Eric Lippert; Pierre Dubus; Sandrine Dabernat; Thibaud Mautuit; Bruno Cardinaud; Catherine Pain; Benoît Rousseau; Magalie Lalanne; Cécile Ged; Yann Duchartre; Emmanuel Richard; Hubert de Verneuil; François Moreau-Gaudry
Journal:  Am J Hum Genet       Date:  2012-07-13       Impact factor: 11.025

6.  Metabolic Landscape of the Mouse Liver by Quantitative 31 P Nuclear Magnetic Resonance Analysis of the Phosphorome.

Authors:  Ganeko Bernardo-Seisdedos; Jon Bilbao; David Fernández-Ramos; Fernando Lopitz-Otsoa; Virginia Gutierrez de Juan; Maider Bizkarguenaga; Borja Mateos; Marcos F Fondevila; Jordi Abril-Fornaguera; Tammo Diercks; Shelly C Lu; Rubén Nogueiras; José M Mato; Oscar Millet
Journal:  Hepatology       Date:  2021-06-15       Impact factor: 17.425

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.